Tag: RA in Czech Republic

Introduction The Czech Republic is an important pharmaceutical market within the European regulatory network. Companies entering the market must navigate EU medicines legislation alongside country-specific requirements administered by the State Institute for Drug Control (SÚKL). Regulatory affairs does not stop when a marketing authorization is obtained. Product information, safety surveillance, regulatory variations, supply obligations, and […]